Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Aims To Leap-Frog Into Next Immuno-Oncology Wave With Aduro

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis hopes its multi-year deal with Aduro Biotech to develop molecules to unlock dormant immune cells by targeting and activating a central signaling pathway called STING will allow it to make up for lost time and catch “the next wave” in immuno-oncology.

Advertisement

Related Content

Aduro Says End Of Janssen Collaborations “Not A Lethal Blow”
Where Does Novartis Go From Here In Oncology? A Conversation With Its Oncology, Gene Therapy Execs
Biopharma Quarterly Dealmaking Statistics, Q1 2015
Deal Watch: Teva Boosts CNS Portfolio With $3.2 Billion Purchase Of Auspex
A New Industry-Academic Model: Novartis And Penn Make A Splash In Cancer Immunotherapy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078357

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel